Introduction {#Sec1}
============

*EMSY* amplification in sporadic breast and ovarian cancer mimics the activity of *BRCA2* mutations in the development of this disease's hereditary form (Hughes-Davies et al. [@CR34]). *EMSY* encodes a large nuclear protein that binds to the BRCA2 N-terminal domain encoded by exon 3 of the *BRCA2* gene (BRCA2~ex3~). Adjacent to the EMSY N-terminal domain that interacts with BRCA2~ex3~ reside conserved residues that specifically bind chromatin-remodeling HP1β and BS69 proteins, implicating EMSY in chromatin regulation. Whereas BRCA2~ex3~ possesses intrinsic histone acetyltransferase (HAT) activity, chromatin-relaxation activity required for transcription, replication and recombination/repair, HP1β binds to methylated histones involved in chromatin assembly that usually impedes these processes. A role for EMSY in chromatin regulation is also suggested by the findings that overexpression of a truncated form of *EMSY* represses the transactivation potential of BRCA2~ex3~ and induces chromosomal instability (CIN), implicating BRCA2 in the development of non-familial cancer as well (Hughes-Davies et al. [@CR34]; Raouf et al. [@CR52]).

However, BRCA2~ex3~ may also be directly involved in the maintenance of chromosomal stability through its interaction with RPA, single-strand DNA (ssDNA)-binding replication protein A, and PALB2, two proteins required for development of the DNA-damage response (DDR), including BRCA2/RAD51-mediated homologous recombination (HR) repair of DNA double-strand breaks (DSBs) (Wong et al. [@CR72]; Xia et al. [@CR73]), a well-established function of BRCA2 (Thorslund and West [@CR60]; Moynahan and Jasin [@CR48]). Generally, DSBs, such as those generated by mega-endonucleases (i.e., I-*Sce*I), ionizing radiation (IR), DNA cross-linking agents or by overexpressing oncogenes, activate the DDR orchestrated by PIKKs, the serine/threonine PI3K-like kinases ATM, ATR and DNA-PK, which, once recruited/localized at sites of such lethal damage, trigger a cascade of phosphorylation events in several downstream target proteins that coordinate DNA-damage checkpoints (i.e., cell-cycle arrest) with recombination/repair or activate p53-dependent or -independent apoptosis/senescence (Shiloh [@CR55]; Kastan and Bartek [@CR38]; Harper and Elledge [@CR31]; Branzei and Foiani [@CR10]; Halazonetis et al. [@CR30]).

Briefly, while PALB2 links BRCA2 to BRCA1, which localizes PALB2/BRCA2/RAD51 complex at chromatin and I-*Sce*I/IR-induced DSBs (Xia et al. [@CR73]; Zhang et al. [@CR79]), RPA coats ssDNA and recruits ATR through its interacting protein ATRIP, after the localization of activated ATM and the processing of DSB ends into ssDNA by BRCA1 and MRE11/RAD50/NBS1 (MRN) complex (Kastan and Bartek [@CR38]; Jazayeri et al. [@CR37]). In addition, through its interaction with MRN, RPA also recruits ATR/ATRIP to ssDNA tracts at stalled forks, generated spontaneously or induced by ultraviolet (UV) light, hydroxyurea (HU) or methyl methane sulfonate (MMS) (Harper and Elledge [@CR31]; Olson et al. [@CR49]). MRN is the DNA-binding/bridging/unwinding/exonuclease component of BRCA1-associated genome surveillance complex (BASC) that also contains BARD1 (BRCA1-associated ring domain), ATM, ATR, the DNA-helicase BLM, and replication factors that load DNA-polymerase processivity factor proliferating cell nuclear antigen (PCNA) on the forks (Wang et al. [@CR68]; Greenberg et al. [@CR27]). BRCA1/MRN not only localizes ATM, ATR and BRCA2/RAD51 complexes at sites of DNA damage, but also facilitates the ability of ATR and ATM to interact with and phosphorylate several downstream targets, most notably, their proximal effector checkpoint-kinases CHK1 and CHK2, respectively, and the cohesin subunit SMC1 (structural maintenance of chromosome 1). Whereas CHK1 and CHK2 target the cyclin-dependent kinases CDK1 and CDK2 for inactivation, thereby imposing G1/S and G2/M checkpoints, SMC1 enhances sister chromatid (SC) cohesion (SCC) to keep them perfectly aligned for BRCA2/RAD51-mediated HR, thus ensuring error-free repair of DNA damage, replication-fork progression and SC segregation, thereby maintaining chromosomal stability in both structure and number (Shiloh [@CR55]; Kastan and Bartek [@CR38]; Branzei and Foiani [@CR10]; Moynahan and Jasin [@CR48]).

In addition to RPA and PALB2, evidence indicates that BRCA2 may also employ EMSY in DDR development. (a) The inherited, cancer-eliciting BRCA2~ex3~ mutations that inactivate its transactivation potential and block its binding to EMSY (Hughes-Davies et al. [@CR34]) also abrogate its interaction with RPA (Wong et al. [@CR72]) and PALB2 (Xia et al. [@CR73]); (b) EMSY localizes to IR-induced DNA damage/repair foci (Hughes-Davies et al. [@CR34]) in a manner similar to BRCA2 co-localizing with BRCA1, BARD1, MRN, RPA, RAD51 and ATR at UV-stalled forks, marked by PCNA (Scully and Livingston [@CR53]); (c) EMSY-interacting HP1β protein binds to CAF-1, the histone chaperone chromatin-assembly factor that interacts with PCNA (Groth et al. [@CR28]), and like BRCA2, CAF-1 also stabilizes replication forks; in its absence, stalled forks can collapse into DSBs (Lomonosov et al. [@CR43]; Ye et al. [@CR76]). CAF-1/PCNA ensures the loading of acetylated histones behind replication forks (Groth et al. [@CR28]), whereas BRCA2 may use EMSY/HP1β to provide such histones by displacing nucleosomes ahead of such forks, allowing fork movement and RPA coating of nascent ssDNA and recruiting/activating ATR; and (d) overexpression of a truncated form of *EMSY* in human mammary epithelial cells induces SC-type abnormalities displayed by BRCA2-deficient cells (Raouf et al. [@CR52]). Collectively, these findings raise the hypothesis that increased EMSY level may mimic BRCA2 deficiency in CIN, at least by overriding RPA and PALB2.

To gain insights into this scenario, we increased EMSY level in sporadic breast cancer MCF-7 cells and determined whether it induces other phenotypes of BRCA2 deficiency. In addition to SC-type abnormalities \[quadri-radial chromosomes, breakage, tri-radial chromosomes, chromosome loss/gain (aneuploidy/polyploidy), deletions, amplifications, inversions, and translocations\], BRCA2-deficient cells also exhibit (a) a deficit in HR repair of I-*Sce*I-induced DSBs; (b) normal efficiency of DSB repair by the error-prone, non-homologous end joining (NHEJ) pathway; (c) heightened efficiency of DSB repair by ssDNA annealing (SSA), a RAD51-independent gene deletion process restricted to DSBs generated between direct repeats; (d) hypersensitivity to MMS, HU, UV, IR and chemotherapeutic, DSB-inducing agents; (e) defective G2/M checkpoint; (f) an amplified rate of both gene mutations and reversions; (g) a hyper-recombination phenotype, characterized by an increased rate of spontaneous HR, gene conversion, inversion and deletion/amplification (crossover) events; and last but not least (h) an augmented rate of spontaneous SC replication slippage (SCRS), a RAD51-independent gene deletion/amplification process (Scully and Livingston [@CR53]; Venkitaraman [@CR61]; Abaji et al. [@CR1]; Gudmundsdottir and Ashworth [@CR29]; Moynahan and Jasin [@CR48]). These phenotypes are also characteristic features of BRCA1-deficient cells, except that they exhibit a deficit in DSB repair by SSA (Scully and Livingston [@CR53]; Venkitaraman [@CR61]; Cousineau et al. [@CR17]; Gudmundsdottir and Ashworth [@CR29]; Moynahan and Jasin [@CR48]).

These findings indicate that EMSY-overexpressing MCF-7 cells only partially mimic BRCA-deficient tumor cells. They exhibit both an enhanced rate of SCRS and decreased efficiency of HR repair of I-*Sce*I-induced DSBs, but show a decreased rate of spontaneous HR and normal efficiency of DSB repair by SSA, suggesting that increased EMSY level interferes with the recruitment/activation of ATR without affecting that of ATM or the processing of DSB ends into ssDNA by BRCA1/MRN or the ability of BRCA2/RAD51 to bind/stabilize ssDNA. We extensively discuss the molecular details of how this can happen, to appreciate all phenotypes of BRCA deficiency as markers of deregulated HR orchestrating at least S/G2/M-transition checkpoints and gene mutation-avoidance systems.

Materials and methods {#Sec2}
=====================

DNA manipulations, cell lines, culture, and DNA transfections {#Sec3}
-------------------------------------------------------------

Three distinct recombination/repair reporter MCF-7 cell lines were transfected with pcDNA3.1*Neo*-based expression vector, with or without short *EMSY* (1--478) (Hughes-Davies et al. [@CR34]), using FuGENE 6 transfection reagent (Boehringer-Mannheim, Indianapolis, IN). Forty-eight hours later, the transfected cells were cultured in medium containing G418 (600 μg/mL). Independent G418^R^ cell clones were picked and amplified individually to analyze short *EMSY* integration and its expression by PCR, RT-PCR and Western blotting.

PCR {#Sec4}
---

Genomic DNA was extracted from individual cell clones, and 400 ng subjected to PCR with the following primer pair: EMSY37-F (5′-agggatgaatgcaaaagaat-3′) and pcDNA3.1Neo-R (5′-tctgagatgagtttttgttc-3′), which specifically amplifies a fragment of 1,397 bp from exogenous *EMSY* but not endogenous *EMSY*.

RT-PCR {#Sec5}
------

RNA was extracted from individual cell clones with Trizol reagent and transcribed to cDNA with reverse transcriptase and primers (hexamers) from the SuperScript First-Strand Synthesis System RT-PCR kit (Invitrogen, Carlsbad, CA). The same primer pair described for PCR was employed to amplify exogenous *EMSY* cDNA. In the same reaction tube, *EMSY*1810-R (5′-ttttctcctccagcatttag-3′) was added to amplify, together with *EMSY*37-F, a 1,773-bp fragment from endogenous wild-type (wt) *EMSY*. In reaction controls, the primer pair 18s-F (5′-tgaggccatgattaagaggg-3′) and 18s-R (5′-cgctgagccagttcagt gtag-3′) amplified a 642-bp fragment of ribosomal RNA. *Puro*^R^, *Hyg*^R^, and *BRCA2* expression was assessed with *Puro*-F (5′-cgaccttccatgaccgagta-3′) and *Puro*-R (5′-gccttccatctgttgctg-3′), *Hyg*-F (5′-cggcgagtacttctacacagc-3′) and *Hyg*-R (5′-ttcgaacacgcagatgcagtcg-3′), *BRCA2*-F (5′-ccaagtcatgccacacattc-3′) and *BRCA2*-R (5′-ttgaccaggtgcggtaaaat-3′). In addition, *RAD51* expression was analyzed with the primer pair *RAD51*-F (5′-gagtaatggcaatgcagatgca-3′) and *RAD51*-R (5′tcgacccgagtagtctgttct-3′). PCR amplifications were undertaken with the Expand High Fidelity PCR System kit (Boehringer-Mannheim).

Protein manipulations {#Sec6}
---------------------

Proteins were extracted and quantified as described previously (Abaji et al. [@CR1]). Fifty micrograms of protein extract was separated on 8% sodium dodecyl sulfate-polyacrylamide gel, transferred to nitrocellulose membranes (Amersham, Piscataway, NJ) and probed with crude rabbit antisera (1/3,000) directed against EMSY. For RAD51 detection, 50 μg of protein extracts was separated on 12.5% gel and probed with mouse anti-RAD51 antibody (51RAD01, Calbiochem, La Jolla, CA) with actin as loading control (ACTN05, Medicorp, Montreal, QC, Canada).

HR frequency and rate {#Sec7}
---------------------

HR rate and frequency were determined from at least two to three independent experiments, respectively, as described previously (Lemelin et al. [@CR41]). Briefly, in each experiment and for each cell line, 12 independent cultures (1--100 cells) were plated in parallel and cultured to confluence. Cells were trypsinized, counted, and a portion was taken for plating efficiency estimation. 5 × 10^5^ cells were plated 24 h before adding Puro at 1.0 μg/mL. Since HR between direct repeats can delete *Hyg*^*R*^ during culture, direct-repeat cell lines were maintained without hygromycin before Puro selection. The number of Puro^R^ colonies divided by the number of plated cells determined HR frequency. The HR rate was calculated from these frequencies by the fluctuation test.

For I-*Sce*I-induced HR experiments, the vectors pβactin*SceI* and pFRED25, which express the meganuclease I-*Sce*I and green fluorescent protein (GFP), respectively, were co-transfected into 2 × 10^5^ cells with FuGENE 6. In parallel experiments, the same number of cells was transfected with pFRED25 and pMC1*Neo*, the latter to correct for DNA content as a control for I-*Sce*I efficiency. GFP-expressing cells were counted 48 h after transfection to examine the efficiency of transfection and normalize HR frequencies. Puro selection was performed 10 days after transfection. The frequency of I-*Sce*I-induced HR was calculated by dividing the number of Puro^R^ colonies transfected with I-*Sce*I by the number of Puro^R^ colonies transfected with control DNA and normalized for transfection efficiency.

Statistical analysis {#Sec8}
--------------------

HR frequencies and rates were assessed by one-way ANOVA. For the analysis of recombination/repair pathways, contingency tables were used with the Chi-square test.

Results {#Sec9}
=======

Experimental strategy {#Sec10}
---------------------

The MCF-7 cell lines employed as backgrounds for *EMSY* overexpression each carries a single, intact copy of a recombination/repair construct containing either a direct-repeat or an inverted-repeat of two inactive *Puro*^R^ genes separated by the *Hyg*^R^ gene (Fig. [1](#Fig1){ref-type="fig"}; Lemelin et al. [@CR41]). Deleting *Eag*I and *Bss*HII restriction sites and inserting one I-*Sce*I cleavage site inactivated the full-length *Puro* gene, whereas the wt *Puro* gene contained an inactivating 5′ deletion, including the promoter. A recombination/repair event between the two *Puro* cassettes would reconstitute a functional *Puro*^R^ gene through loss of I-*Sce*I and gain of wt *Eag*I/*Bss*HII sites, restoring resistance to the drug puromycin in colony assay.Fig. 1Homologous recombination (HR) between direct and inverted repeats. HR reconstitutes a functional *Puro*^R^ gene through loss of the I-*Sce*I site and gain of *Eag*I/*Bss*HII sites. Since I-*Sce*I insertion mutation in *ScePuro* entails the deletion of *Eag*I and *Bss*HII sites, only error-free HR repair events between the two *Puro*^R^ cassettes can restore a functional *Puro* gene. Gene conversion restores one functional *Puro* gene without affecting the overall structure of the locus, whereas crossover associated or not with gene conversion inverts *Hyg*^R^ gene between inverted *Puro* repeats (**a**) or deletes *Hyg*^R^ between direct *Puro* repeats (**b**). Deletion events can also result from SCRS or SSA (see text)

In this type of assay system (Moynahan and Jasin [@CR48]), the efficiency of recombination/repair also depends on the ability of a cell to at least survive the damage and express the reporter gene. It has been consistently demonstrated with various organisms that when more than two copies of a reporter gene lie adjacent to one another, the tandem can undergo chromatin assembly and transcription repression, an epigenetic phenomenon known as homology- or repeat-induced gene silencing (HIGS or RIGS) that resembles position-effect variegation, in which chromatin assembly can spread into adjacent domains (Henikoff [@CR32]). The use of single-copy MCF-7 cell clones would thus prevent repression of *Puro*^R^ gene by HIGS. In addition, the *Puro*^R^ gene was also designed to escape repression from the adjacent marker *Hyg*^R^ gene (Lemelin et al. [@CR41]). It has also been consistently shown in various organisms that in such cell clones, which had initially been selected for the expression of a marker gene, the adjacent reporter gene was usually repressed (Villemure et al. [@CR64]; Eszterhas et al. [@CR22]). Such an HIGS-independent, gene-silencing phenomenon, termed 'transcriptional interference' and 'promoter suppression', can occur whether adjacent transcription units are arranged in direct or inverted orientations. Transcriptional interference/suppression is cis-acting, epigenetic and heritable. Since EMSY interacts with CAFs and its increased level represses the transcription of reporter genes (Hughes-Davies et al. [@CR34]), a transcription interference/suppression-free assay system was considered necessary for this study.

Nevertheless, we investigated the effect of increased EMSY level on the expression of *Hyg*^R^ and *Puro*^R^ genes at distinct loci. *Hyg*^R^ expression is driven by the Herpes simplex virus thymidine kinase (*TK*) gene promoter, whereas that of *Puro*^R^ is under control of the strong cellular-housekeeping phosphoglycerate kinase gene promoter (Lemelin et al. [@CR41]). MCF-7 cells exhibit normal *EMSY* copy number and expression level, whereas overexpression of a truncated *EMSY* form, containing the binding sites of BRCA2, HP1β and BS69, represses both BRCA2~ex3~-transactivation potential and expression of a *TK* gene promoter in transient assays (Hughes-Davies et al. [@CR34]). To examine this in stable MCF-7 cell clones, the three distinct reporter cell lines dA9, iA12 and iA7, grown in Hyg-free medium, were transfected with pcDNA3.1*Neo* containing or not short *EMSY* (Hughes-Davies et al. [@CR34]). Since DNA transfection per se can activate DDR (Igoucheva et al. [@CR35]) and DDR activation can repress both p53-dependent and -independent gene expression (Zhou et al. [@CR81]), and p53 can repress all viral promoters driving the expression of reporter genes (Lemelin et al. [@CR41]), independent *Neo*^R^ cell clones were picked, amplified and only then analyzed by PCR of genomic DNA, RT-PCR and Western blotting. Direct-repeat (dA9) and inverted-repeat (iA12 and iA7) cell lines presented similar expression levels of either endogenous or exogenous *EMSY* (Fig. [2](#Fig2){ref-type="fig"}). However, the slight increase in EMSY protein level did not repress *Hyg*^R^, since individual *Neo*^R^ cell clones, grown in parallel in G418- and Hyg-containing media, showed similar plating efficiency. In addition, no apparent change in *Hyg* or *Puro* expression was noted at the RNA level (data not included).Fig. 2Short *EMSY* expression in MCF-7 cell lines. PCR of genomic DNA was performed to demonstrate *EMSY* transgene integration. The primer pair employed amplifies only the *EMSY* transgene. Its mRNA was analyzed by qualitative RT-PCR with the same primer pair. As a control, a fragment from endogenous full-length *EMSY* was amplified in the same reaction. 18S rRNA was amplified as a control for RT-PCR. Water or no reverse transcriptase served as a negative control, whereas *EMSY-*expressing vector DNA was used as a positive control. EMSY proteins were assessed by Western blotting. All the different EMSY cell lines examined are independent cell clones

Short EMSY represses spontaneous RAD51-mediated HR {#Sec11}
--------------------------------------------------

One can envisage at least four more mechanisms by which short EMSY may affect spontaneous HR (i.e., without exposure to exogenous DNA-damaging agents). First, it may override PALB2 and thereby target BRCA2 for degradation in a manner similar to PALB2 depletion (Xia et al. [@CR73]). Second, it may induce a BRCA2 conformational change that may affect its ability to interact and/or co-localize with RAD51, DSS1, or FANC-D2 at sites of DNA damage (Gudmundsdottir and Ashworth [@CR29]). These proteins interact with the BRCA2 C-terminal domain, and deletion of such a domain or disruption of its interacting proteins has been shown to mimic *BRCA2* deficiency, as revealed by decreased efficiency of HR repair of I-*Sce*I-induced DSBs and hypersensitivity to PARP1 inhibitors and DSB-inducing agents (Gudmundsdottir and Ashworth [@CR29]; Moynahan and Jasin [@CR48]). In addition, deletion of the human BRCA2 C-terminal domain also increases the rate of spontaneous HR (Abaji et al. [@CR1]). Thus, in either scenario, *EMSY*-overexpressing cell lines would exhibit all these phenotypes, as BRCA2-deficient CAPAN-1 cells do (Abaji et al. [@CR1]).

Third, short EMSY may directly repress the expression of *RAD51* gene or its transactivator *PTEN*, since cells depleted of *PTEN* also undergo SC-type abnormalities similar to *RAD51*-deficient cells (Shen et al. [@CR54]), BRCA2-deficient cells (Venkitaraman [@CR61]) or short *EMSY*-expressing cells (Raouf et al. [@CR52]). Fourth, it may override PALB2 and RPA, and thereby quench BRCA2 without affecting its stability. In these two scenarios, short *EMSY*-expressing cells would be expected to exhibit a hypo-recombination phenotype by decreasing the rate of spontaneous HR.

To examine which scenario is more likely, single Neo^R^/Hyg^R^, inverted-repeat MCF-7 cell clones and EMSY-overexpressing derivatives were grown in parallel and subjected to Puro selection. In contrast to direct repeats, inverted repeats monitor exclusively RAD51-mediated HR: gene conversion and crossover (inversion) events (Fig. [1](#Fig1){ref-type="fig"}). EMSY-overexpressing MCF-7 cell lines displayed 4--16-fold decreases in the rate of spontaneous HR, compared to their parental cell lines containing the empty vector (Table [1](#Tab1){ref-type="table"}). In addition, no apparent difference in *RAD51* or *BRCA2* gene expression was noted between parental and derivative cell lines (Fig. [3](#Fig3){ref-type="fig"}). Since BRCA2 can bind only 20% of the cellular RAD51 pool (Marmorstein et al. [@CR44]; Yu et al. [@CR77]), these findings indicate that short EMSY repressed at least free RAD51 molecules.Table 1Effect of EMSY on spontaneous inverted-repeat HRCell linesFrequency^a^Ratio^b^Rate^c^Ratio^d^iA72.05 ± 0.7 × 10^−4^4.94 ± 0.7 × 10^−5^iA7/EMSY-3B3.25 ± 1.6 × 10^−5^6.37.97 ± 1.0 × 10^−6^6.2iA7/EMSY-62.86 ± 1.4 × 10^−5^7.27.24 ± 0.9 × 10^−6^6.8iA7/EMSY-95.61 ± 2.9 × 10^−5^3.71.14 ± 0.4 × 10^−5^4.3iA7/EMSY-311.30 ± 0.5 × 10^−5^15.83.33 ± 0.8 × 10^−6^14.8iA122.24 ± 1.0 × 10^−3^3.25 ± 1.0 × 10^−4^iA12/EMSY-132.76 ± 1.1 × 10^−4^8.14.83 ± 1.2 × 10^−5^6.7iA12/EMSY-189.73 ± 2.3 × 10^−5^23.02.03 ± 0.6 × 10^−5^16.0^a^Frequency is determined as the number of Puro^R^ cell clones relative to the total number of viable cells before selection^b^Ratio (parent/EMSY-expressing derivative cell lines) indicates recombination fold decrease in EMSY-expressing cells relative to their parents (*p* \< 0.0001)^c^Rate represents the number of recombination events/locus/cell/generation^d^Ratio (parent/EMSY-expressing derivative cell lines) (iA7, *p* = 0.0003; iA12, *p* = 0.0236)Fig. 3Effect of short EMSY on *BRCA2* and *RAD51* expression. RT-PCR reveals no apparent effect of short EMSY on *RAD51* or *BRCA2* expression levels. 18S rRNA was amplified as a control for RT-PCR. Water or no reverse transcriptase was a negative control. Western blotting analysis indicates no apparent effect of short EMSY on RAD51 protein level. Actin served as loading control

Short EMSY heightens the rate of spontaneous SCRS {#Sec12}
-------------------------------------------------

If short EMSY were to suppress spontaneous HR by interfering solely with free RAD51 molecules, one would expect no effect on SCRS, since the process is RAD51-independent and yet down-regulated by both BRCA1 and BRCA2 (Abaji et al. [@CR1]; Cousineau et al. [@CR17]). To examine this, we tested direct-repeat cell lines that monitor a mixture of HR and SCRS (Fig. [1](#Fig1){ref-type="fig"}). However, short EMSY did not affect the rate of *Puro*^R^ colony formation with direct repeats, but significantly shifted gene conversion to deletion events (Table [2](#Tab2){ref-type="table"}), as revealed by PCR analysis of the recombinants (Abaji et al. [@CR1]). The increase in deletion cannot be attributed to augmented crossover, since short EMSY represses such HR events at inverted repeats (Table [1](#Tab1){ref-type="table"}). In addition, neither BRCA2 nor BRCA1 represses crossover in favour of gene conversion as the RAD51-interacting BLM or WRN helicase does with HR intermediates containing crossed DNA strands: Holliday junctions (HJs) (Abaji et al. [@CR1]; Cousineau et al. [@CR17]). Collectively, these findings indicate that short EMSY not only interferes with free RAD51 molecules and BRCA2/RAD51 complexes, but also disrupts SCC/alignment.Table 2Effect of EMSY on spontaneous direct-repeat HRCell linesFrequencyRatioRateRatioGC (%)SCRS (%)dA92.99 ± 0.8 × 10^−6^6.56 ± 0.9 × 10^−7^34/36 (94)2/36 (6)dA9/EMSY-72.30 ± 0.9 × 10^−6^1.35.31 ± 0.8 × 10^−7^1.212/14 (86)2/14 (14)dA9/EMSY-92.32 ± 0.7 × 10^−6^1.35.35 ± 0.9 × 10^−7^1.29/11 (82)2/11 (18)dA9/EMSY-162.87 ± 0.7 × 10^−6^1.05.72 ± 0.7 × 10^−7^1.125/33 (76)8/33 (24)dA9/EMSY-192.55 ± 1.0 × 10^−6^1.25.84 ± 0.7 × 10^−7^1.156/92 (61)36/92 (39)dA9/EMSY-203.17 ± 1.4 × 10^−6^0.96.84 ± 1.0 × 10^−7^1.023/30 (77)7/30 (23)Frequencies, rates and ratios were determined as described in Table [1](#Tab1){ref-type="table"}*GC* gene conversionThe apparent absence of EMSY effect on the frequency (*p* = 0.93) and rate (*p* = 0.43) of spontaneous Puro^R^ colony formation appears to be due to a decrease in RAD51-mediated GC events compensated by an increase in RAD51-independent SCRS events (*p* = 0.004)

Short EMSY represses BRCA2/RAD51-mediated HR repair of DSBs {#Sec13}
-----------------------------------------------------------

To examine this, direct-repeat MCF-7 cell lines and EMSY-overexpressing derivatives were transiently co-transfected in parallel with the pβactin/I-*Sce*I vector, which expresses I-*Sce*I, and a GFP-expressing vector, employed to evaluate transfection efficiency. No apparent difference in cell viability was noted after transfection between the parental cell line and *EMSY*-overexpressing derivatives (data not included). When the *Puro* gene is cleaved at the I-*Sce*I site, HR repairs the DSB (Moynahan and Jasin [@CR48]). I-*Sce*I expression increases the frequency of Puro^R^ colony formation with all cell lines, whereas EMSY-overexpressing derivatives consistently present threefold fewer colonies than their parents do (Table [3](#Tab3){ref-type="table"}).Table 3Effect of EMSY on I-*Sce*I-induced HRCell linesFrequency^a^Ratio^b^GC (%)^c^SSA (%)dA9217.63 ± 67.668/74 (92)6/74 (8)dA9/EMSY-781.32 ± 40.32.753/68 (78)15/68 (22)dA9/EMSY-975.59 ± 38.52.966/90 (73)24/90 (27)dA9/EMSY-1670.21 ± 21.33.152/66 (79)14/66 (21)dA9/EMSY-1971.64 ± 33.03.055/78 (71)23/78 (29)dA9/EMSY-2082.45 ± 37.22.647/58 (81)11/58 (19)*GC* gene conversion, *SSA* single-strand annealing^a^Frequency fold induction represents the mean of at least three independent experiments for each cell line (*p* = 0.0064)^b^Ratio indicates recombination fold decrease in EMSY-expressing cells relative to their parents^c^EMSY shifts the proportion of GC events to SSA (*p* = 0.029); the absolute value of SSA events remained unchanged but their proportion increased in comparison to the decreased number of GC events

HR repair of I-*Sce*I-induced DSBs between direct repeats occurs almost exclusively by gene conversion with few deletion events attributed to SSA (Cousineau and Belmaaza [@CR18]; Moynahan and Jasin [@CR48]). SSA, which obligatorily leads to deletion between direct repeats, cannot be monitored with inverted repeats, since the processing of DSB ends by BRCA1/MRN and ATM would generate identical rather than complementary ssDNA ends that would anneal (Fig. [1](#Fig1){ref-type="fig"}). Consistent with BRCA2/RAD51 complexes acting downstream of BRCA1/MRN (Greenberg et al. [@CR27]; Zhang et al. [@CR79]; Moynahan and Jasin [@CR48]), the efficiency of DSB repair by SSA decreases in BRCA1-deficient cells and increases in RAD51- or BRCA2-deficient cells at the expense of reduced gene conversion (Daboussi et al. [@CR19]; Abaji et al. [@CR1]; Cousineau et al. [@CR17]; Gudmundsdottir and Ashworth [@CR29]). To determine whether short EMSY also affected DSB repair by SSA, we investigated the structure of I-*Sce*I-induced recombinants by PCR (Abaji et al. [@CR1]). Taking into consideration the threefold decrease in the overall frequency of I-*Sce*I-induced HR, PCR analysis indicates that short EMSY lowers the efficiency of gene-conversion repair by 3.7-fold and shifts DSB repair from gene conversion to SSA, without affecting the efficiency of the latter (Table [3](#Tab3){ref-type="table"}).

Discussion {#Sec14}
==========

Briefly, our findings indicate that an increased level of the EMSY N-terminal domain only partially mimics BRCA2 deficiency. Similar to BRCA2-deficient CAPAN-1 cells (Abaji et al. [@CR1]), EMSY-overexpressing MCF-7 cells also exhibit an increased rate of SCRS and a deficit in HR repair of I-*Sce*I-induced DSBs. However, unlike CAPAN-1 cells that present an increased rate of spontaneous HR and heightened efficiency of DSB repair by SSA (Abaji et al. [@CR1]), EMSY-overexpressing MCF-7 cells rather display a decreased rate of the former and normal efficiency of the latter.

The differential effect of short EMSY on these processes, together with the lack of influence on expression of the reporter genes *Hyg* and *Puro* at three distinct loci and endogenous *RAD51*, *BRCA2* and *EMSY*, seems to argue against EMSY as a general chromatin-assembly factor/transcription repressor. The lack of effect on gene expression could not be attributed to the slight elevation of EMSY level in MCF-7 cell lines, as a higher level of a similar truncated form of *EMSY* in a telomerase-immortalized human breast epithelial cell line also does not affect *BRCA2*, *BRCA1*, *p53* or *p21* expression (Raouf et al. [@CR52]). In addition, it also does not much affect the stability of BRCA2 protein or its ability to interact and/or co-localize with RAD51, since this would confer hyper-recombination as BRCA2 deficiency does (Abaji et al. [@CR1]). Rather, short EMSY bestows hypo-recombination by decreasing the rate of spontaneous HR, presumably by enhancing the repressive effect of BRCA2 on RAD51 (Abaji et al. [@CR1]).

Both the promotion of RAD51 activity by BRCA2 in response to I-*Sce*I-induced DSBs and its repression in the absence of such lethal damage were thought to be orchestrated by BRCA1, ATR and ATM (Abaji et al. [@CR1]; Cousineau et al. [@CR17]). Consistent with this view are the findings that, in undamaged human cells, the BRCA2 C-terminal RAD51-binding motif ser3291 encoded by exon27 (BRCA2~ex27~) is phosphorylated by CDK1, a post-translational modification that blocks its interaction with RAD51 (Thorslund and West [@CR60]). However, after the induction of DSBs that inactivate CDK1, BRCA2~ex27~ becomes de-phosphorylated, and its ability to both bind RAD51 and carry out HR repair of such lethal damage is restored (Thorslund and West [@CR60]). RAD51 is functional as oligomers (1 oligomer contains 6 or 7 RAD51 monomers) that coat 3′-ssDNA and form a nucleoprotein filament that undertakes the DNA strand-exchange reaction by invading an intact homologous DNA (dsDNA) to prime new DNA synthesis and thus repair the damage (Thorslund and West [@CR60]). Whereas the eight BRC repeats encoded by exon 11 (BRCA2~ex11~) can bind both RAD51 monomers and oligomers, BRCA2~ex27~, which is unrelated to BRC repeats, exclusively binds RAD51 oligomers or RAD51 filament (Thorslund and West [@CR60]). Since BRCA2 can bind only 20% of the cellular RAD51 pool (Marmorstein et al. [@CR44]; Yu et al. [@CR77]), one way by which short EMSY could repress both spontaneous HR and HR repair of DSBs is to both disrupt RAD51 oligomers into monomers and maintain BRCA2~ex27~ phosphorylation.

EMSY-overexpressing MCF-7 cells exhibit approximately a fourfold decrease in the efficiency of HR repair of I-*Sce*I-induced DSBs similar to BRCA1- or BRCA2-deficient tumor cells (Abaji et al. [@CR1]; Cousineau et al. [@CR17]), or hypoxic human cells, since hypoxia also decreases the synthesis of HR proteins to offset chemo- and radio-resistances (Chan et al. [@CR13]). Consistently, a similar decrease has also been reported with cells repressed or disrupted in BARD1 (Westermark et al. [@CR71]); MRN (Yang et al. [@CR75]); BRIP1 (BRCA1-interacting protein, also known as the helicase BACH1) (Litman et al. [@CR42]); CtIP that links BRCA1 to MRN (Chen et al. [@CR14]); ATM (Golding et al. [@CR26]); ATR (Wang et al. [@CR67]); CHK2 (Zhang et al. [@CR80]); CHK1 (Sorensen et al. [@CR57]); PALB2 (Xia et al. [@CR73]); RPA (Sleeth et al. [@CR56]); or RAD51 (Daboussi et al. [@CR19]). Since short EMSY neither represses the expression of HR reporter genes nor affects SSA efficiency, the fourfold decrease in HR repair of I-*Sce*I-induced DSBs cannot be ascribed to chromatin assembly diminishing DNA accessibility to transcription factors and restriction enzymes (Villemure et al. [@CR64]). Rather, it could be due to either reduced efficiency of RAD51-mediated DNA strand-exchange/invasion or I-*Sce*I-induced cell death (apoptosis) or permanent cell-cycle arrest (senescence), in which case the essential role of HR in cell survival would be at least checkpoint rather than DSB repair per se. Consistent with this view, (a) all these HR mutant cells are hypersensitive to DSB-inducing agents that activate p53-dependent or independent apoptosis/senescence; (b) after p53 disruption or repression, the efficiency of HR repair of I-*Sce*I-induced DSBs increases by up to 20-fold, whereas the rate of spontaneous HR remains unchanged in the absence of such lethal damage (Akyuz et al. [@CR3]; Lemelin et al. [@CR41]); and (c) similar to BRCA1, both BRCA2 and RAD51 bind p53, and BRCA2/RAD51 complex represses the expression of p53-responsive genes in transient assays (Marmorstein et al. [@CR44]). In such assays, DNA transfection per se can activate DDR, specifically the ATR/ATM pathway (Igoucheva et al. [@CR35]), and DDR activation can repress both p53-dependent and independent gene expression (Zhou et al. [@CR81]), and p53 can repress not only cellular genes but also all viral promoters that drive the expression of HR/transcription-reporter genes (Lemelin et al. [@CR41]). Thus, since the I-*Sce*I assay system does not discriminate between checkpoint/repair and apoptosis/senescence, short EMSY may affect all DDR aspects.

However, short EMSY does not seem to interfere with the localization of activated ATM, the processing of DSB ends into ssDNA by BRCA1/MRN or the stability of ssDNA ends. If it were to negatively affect any of these processes, one would have expected a similar decrease in the efficiency of DSB repair by SSA, which also requires all these HR proteins, except BRCA2/RAD51 complex that would shift DSB repair from SSA to gene conversion (Abaji et al. [@CR1]; Gudmundsdottir and Ashworth [@CR29]; Moynahan and Jasin [@CR48]). Rather, short EMSY shifted DSB repair from gene conversion to SSA without affecting the efficiency of the latter. Thus, it seems that short EMSY interferes with free RAD51 molecules and the loading of RAD51 oligomers by BRCA2~ex27~ at least at DSBs (Thorslund and West [@CR60]), without affecting the ability of BRCA2/RAD51 to bind/stabilize ssDNA and promote SSA.

The SSA-promoting activity of BRCA2 has been appreciated with human full-length BRCA2 in CAPAN-1 cells (Abaji et al. [@CR1]), and with its mini-homologs Brh2 in the smut, yeast-like fungus *Ustilago maydis* and CeBRC2 in *C. elegans* (Petalcorin et al. [@CR50]; Mazloum et al. [@CR45]). However, evidence indicates that in mammals, the SSA-promoting activity of BRCA2 may be overshadowed in the context of at least RPA/BRCA2/RAD51 complex and may become apparent only after the loss of either component of this complex. (a) In RAD51-disrupted cells that exhibit increased efficiency of SSA at I-*Sce*I-induced DSBs (Daboussi et al. [@CR19]), RPA/BRCA2 could still bind/stabilize ssDNA ends and promote SSA, given that similar to RPA and RAD51, BRCA2 also binds ssDNA, its C-terminal domain contains both ssDNA and dsDNA-binding motifs (Thorslund and West [@CR60]). (b) Likewise, in BRCA2-disrupted cells that also display heightened efficiency of SSA at I-*Sce*I-induced DSBs (Abaji et al. [@CR1]; Gudmundsdottir and Ashworth [@CR29]), RPA/RAD51 could still bind ssDNA ends and promote SSA. However, in this case, the ability of RAD51 alone to bind and displace RPA from ssDNA and form RAD51 filament to carry out DNA strand-exchange/invasion, as it does in vitro (Stauffer and Chazin [@CR58]) and in CAPAN-1 cells causing hyper-recombination (Abaji et al. [@CR1]), is crippled by I-*Sce*I-induced DSBs (Abaji et al. [@CR1]). In response to DSBs, ATM and its BRCA1-interacting tyrosine kinase c-ABL, another downstream target of DNA-PK, as well as ATR proximal kinase CHK1, each phosphorylates RAD51 (Daboussi et al. [@CR19]; Shiloh [@CR55]; Sorensen et al. [@CR57]).

It has been shown that RAD51 phosphorylation cripples the ability of RAD51 to both bind ssDNA and undertake DNA strand-exchange/invasion in vitro and HR repair of I-*Sce*I-induced chromosomal DSBs, presumably by disrupting RAD51 oligomers into monomers and preventing RAD51 oligomerization (Yuan et al. [@CR78]; Daboussi et al. [@CR19]; Conilleau et al. [@CR16]). Thus, in response to DSBs, RAD51 phosphorylation would affect not only its function but also that of BRCA2, since de-phosphorylated BRCA2~ex27~ exclusively binds RAD51 oligomer but not RAD51 monomers (Thorslund and West [@CR60]), raising the question: how does BRCA2/RAD51 complex conduct HR repair of DSBs? Since none of the models proposed for HR in general or for BRCA1/2 function in particular considers such a conundrum, we propose that BRCA2 may have the ability to protect its RAD51 monomers bound by the BRC repeats (exon 11) against phosphorylation (Abaji et al. [@CR1]) (Fig. [4](#Fig4){ref-type="fig"}a).Fig. 4A model for the BRCA2/RAD51 pathway in response to DSBs. Not all proteins and protein--protein interactions are shown and the outlines are for illustration only. **a** After their recruitment by BRCA1/MRN, BRCA2/RAD51 complexes act upstream and downstream of ATR (see text for details). **b** After disruption of nucleosomes and transformation of DSB ends into ssDNA by BRCA1/MRN and ATM (*1*), RPA/BRCA2/RAD51 recruits ATR (*2*) to enhance SCC/alignment before the formation/stabilization of D-loop at which the 3′-ssDNA end primes new DNA synthesis (*3*). ATR recruitment/activation could also occur during or after strand invasion and D-loop formation/stabilization, since transformation of DSB ends into 3′-ssDNA could be performed by the unwinding activity of MRN rather than its exonuclease activity that normally yields 5′-ssDNA ends. In this case, unwinding, strand invasion and D-loop formation/stabilization could occur simultaneously after the search for homology, alignment/pairing between DSB ends and the intact homologous dsDNA partner. In either case, the resulting intermediate can either disassemble, the newly synthesized strand can be displaced by unwinding to anneal with the non-invading 3′-ssDNA end to elicit non-crossover gene conversion only, or be processed to yield gene conversion with or without crossover (*4*). Short EMSY interferes with ATR recruitment/activation by overriding RPA (*5*), without affecting the ability of BRCA2/RAD51 to bind ssDNA and perform SSA (*6*). At D-loops, such as at gene promoters and replication origins, free RAD51 oligomers could also compete with RNA and DNA polymerases for ssDNA and thereby block initiation of transcription, replication and repair until activation/recruitment of PIKKs that would disrupt RAD51 oligomers into monomers. The loading of RAD51 oligomers by BRCA2~ex27~ on ssDNA may also act similarly until disruption of RAD51 filament by post-translational modifications (i.e., phosphorylation, ubiquitylation, sumoylation) that would allow transcription, replication and repair to proceed and thereby resume cell-cycle arrest. In this case, transcription and replication factors could act as cellular GPS (guiding position system) elements, recruiting checkpoint proteins to specific sites. Such BRCA2/RAD51 transcription/replication-checkpoint function could explain why checkpoint-deficient cells exhibit radio-resistant DNA synthesis, a characteristic feature of CIN syndromes, including BRCA-deficiency (see text). Thus, whereas RAD51 oligomer can act as a transcription/replication/repair repressor upstream of PIKKs, BRCA2/RAD51 complex can behave as both an activator and a repressor upstream and downstream of PIKKs, respectively

\(c\) In the absence of RPA, BRCA2/RAD51 could still bind/stabilize ssDNA and promote SSA. Consistently, in in vitro assays, the BRCA2 C-terminal domain, Brh2 or CeBRC2 can displace RPA from ssDNA, load RAD51 oligomer onto the dsDNA--ssDNA junction that mimics one processed DSB end, and promote SSA between RAD51 filament and its complementary ssDNA, provided as linear, circular or embedded in synthetic D-loops (Petalcorin et al. [@CR50]; Mazloum et al. [@CR45]; Thorslund and West [@CR60]; Fig. [4](#Fig4){ref-type="fig"}b).

Since short EMSY does not seem to negatively affect the SSA-promoting activity of BRCA2/RAD51, it must have then interfered at least with the loading of RAD51 oligomer by BRCA2 (Thorslund and West [@CR60]). However, the loading of RAD51 oligomer by BRCA2 at DSBs cannot occur before recruitment/activation of ATR, since BRCA2~ex27~ would be still phosphorylated by CDK1. Then, the supply of RAD51 oligomers for RAD51 filament formation could originate afterwards from the BRC repeats of RPA/BRCA2/RAD51, EMSY/BRCA2/RAD51 and PALB2/BRCA2/RAD51, with each complex providing eight non-phosphorylated RAD51 monomers and, thus, a total of three to four RAD51 oligomers. This may be sufficient for HR repair, given previous demonstrations that only one DSB end can invade the undamaged template and prime new DNA synthesis, whereas the other DSB end can capture the displaced, newly synthesized DNA strand through SSA (Fig. [4](#Fig4){ref-type="fig"}b) or NHEJ under certain circumstances, culminating in deletion, insertion, or amplification events (Belmaaza and Chartrand [@CR6]; Villemure et al. [@CR63], [@CR62]). Thus, by overriding at least RPA, short EMSY could block the recruitment/activation of ATR, not only at stalled forks---increasing the likelihood of their collapse into DSBs (Raouf et al. [@CR52]) as BRCA2 deficiency does (Lomonosov et al. [@CR43])---but also at such DSBs without affecting the localization of ATM or the processing of DSBs into ssDNA ends by BRCA1/MRN. This would decrease SCC/alignment, induce RAD51 phosphorylation, and maintain BRCA2~ex27~ phosphorylation, thereby increasing SCRS and repressing both spontaneous HR and HR repair of DSBs without affecting SSA, as found to be the case.

That EMSY/BRCA2, RPA/BRCA2 and PALB2/BRCA2 complexes have independently been fractionated from undamaged human cells indicates that, similar to PALB2, EMSY and RPA are also partners and stabilizers of BRCA2 (Hughes-Davies et al. [@CR34]; Wong et al. [@CR72]; Xia et al. [@CR73]). However, regardless of their proportions in cells, increased EMSY level would be expected to shift protein concentration equilibrium towards EMSY/BRCA2, overriding PALB2 and RPA by quenching BRCA2 without affecting its overall stability. As it still interacts with HP1β and BS69, short EMSY might also override full-length EMSY. However, notwithstanding the exact role of full-length EMSY, the effects of short EMSY reported here provide evidence that, in addition to chromatin and transcription regulation, BRCA2~ex3~ may also be directly involved in the development of DDR in at least replication/checkpoint and recombination/repair.

Such a heretofore unappreciated function of BRCA2 can be best examined in phenotypes of *BRCA2* knockout (KO) mice. Whereas *BRCA2* null, *BRCA2*^Δex1−5^ and *BRCA2*^Δex11^ KO mice all die at an early embryonic stage in a manner similar to *RPA* and *RAD51* KO mice, *BRCA2*^Δex27^ KO mice are viable and develop normally (Donoho et al. [@CR21]; Evers and Jonkers [@CR23]; Friedberg and Meira [@CR25]), indicating that whereas the function of at least BRCA2~ex3~ and BRCA2~ex11~ in replication/checkpoint is essential, that of BRCA2~ex27~ in RAD51-mediated HR repair of DSBs and resistance to DSB-induced lethality (Thorslund and West [@CR60]; Moynahan and Jasin [@CR48]) is dispensable for cell survival, proliferation and differentiation. The embryonic lethality of *BRCA2* KO mice has been associated with chromosomal breakage and activation of p53, suggesting that: (a) such lethal damage does not arise accidentally in *BRCA2*^Δex27^ KO mice or normal proliferating/differentiating cells; and (b) the essential role of BRCA2 in replication/checkpoint is at least to prevent fork collapse into fatal injury rather than promote RAD51-mediated HR repair of collapsed forks.

Consistently, in response to fork stalling, bacteria, budding or fission yeast do not undergo fork collapse; only replication/checkpoint mutants do, through the activities of HR enzymes (Branzei and Foiani [@CR8]). Such organisms do not possess BRCA homologs and yet they carry out DSB repair almost exclusively by HR. In contrast, in organisms that possess BRCA homologs, NHEJ is the predominant DSB repair pathway, whether at collapsed forks or IR/enzyme-induced DSBs. Therefore, in such evolved organisms, one would expect NHEJ and SSA to rescue HR mutants from DSB-induced lethality. In contrast, KO of HR genes, such as *RPA*, *RAD51*, *BRCA1*, *BARD1*, *MRE11*, *RAD50*, *NBS1*, *ATR*, *CHK1*, *RAD51*B, *RAD51*D, *XRCC*2, *TOP*II, and *BLM*, in mice makes them all undergo chromosomal breakage and succumb to death in a manner similar to *BRCA2* KO mice (Friedberg and Meira [@CR25]). Thus, in addition to their well-established role in HR repair of DSBs, RAD51 and its paralogs RAD51B, RAD51D and XRCCs are also essential for checkpoint/fork stability. Consistent with this aspect, not all RAD proteins required for HR repair of DSBs are essential for survival; *RAD52*, *RAD54* and *RAD51*C KO mice were all found to be viable (Friedberg and Meira [@CR25]).

In addition, ATM, master of the response to DSBs including their repair by HR, NHEJ and SSA, is also dispensable for survival; KO mice remain viable, except that they exhibit hyper-sensitivity to IR, gonadotrophy, infertility, immunodeficiency and thymic lymphoma, since in germ-line cells and lymphocytes, DSBs rather arise in a programmed manner to initiate meiotic HR, ensuring "gene shuffling" and the orderly segregation of homologous chromosomes and thus the formation of healthy gametes, and V(D)J recombination (NHEJ) for immune system development, protecting against infectious diseases and cancer (Friedberg and Meira [@CR25]). In the absence of ATM, such 'heavenly' breaks could trigger apoptosis/senescence and act as anti-cancer barriers in 'specialized' tissues at the expense of their atrophy. Consistently, *ATM*/*RAG1* and *ATM*/*RAG2* double KO (DKO) mice that no longer undergo programmed DSBs and V(D)J recombination also develop CIN and lymphoma (Petiniot et al. [@CR51]). Moreover, other ATM downstream targets that play a role in HR repair of DSBs are also dispensable for survival; *CHK2* and *H2AX* KO mice are as viable as *ATM*/*CHK2* and *ATM*/*H2AX* DKO mice (Friedberg and Meira [@CR25]). Furthermore, NHEJ key components, including DNA-PK, another master of DSBs, Ku70, Ku80, Ku86 and Artemis, except ligase IV, are also dispensable for survival; KO mice remain viable (Friedberg and Meira [@CR25]); and last but not least, genes of mutation-avoidance systems, such as base-excision repair/single-strand break repair (BER/SSBR) of oxidative damage (*XRCC1*, *APEX*, *LIG*1, *POL*β, *FEN*, *PARP1*/*PARP2*), nucleotide-excision repair (NER) and transcription-coupled NER of DNA adducts (*XPD*, *XAB*), or translesion DNA synthesis (TLS) (*REV3*), which are not necessary for DSB repair, all appear to be essential for survival (Friedberg and Meira [@CR25]). Collectively, these findings indicate that (a) checkpoint/fork stability requires the participation of components of all DNA-damage repair mechanisms---HR, SSA, NHEJ, BER/SSBR, NER and TLS---rather than DNA damage/repair per se; (b) the same machinery that responds to programmed DSBs also acts to suppress accidental breakage in both specialized and normal tissues; and (c) DSB has been conceived as a fundamental requirement of life, evolution and death, acting as a 'longevity clock' and 'quality control', eliminating aberrant proliferating/differentiating cells (cancer) and embryos (abortion).

In such replication/checkpoint mutants, the collapse of stalled forks into lethal DSBs has been associated with cleavage of HR intermediates (HJs) resembling a chicken-foot structure that forms as a consequence of "replication-fork reversal" (RFR) or "run-off" of specialized SC junctions resembling hemicatenanes (pseudo-double HJs) (Branzei and Foiani [@CR8]; Fig. [5](#Fig5){ref-type="fig"}). In yeast, pseudo-double HJs have been shown to form during the early S phase, after origin firing, and to migrate, chasing the forks and presumably assisting SCC/alignment until anaphase whereas in human cells, such SC bridges have been reported to form at fragile sites, after replication stress, and at anaphase before their resolution by BLM/TOPIIIα and TOPII and SC segregation as two intact chromosomes (Branzei and Foiani [@CR8], [@CR9]; Chan et al. [@CR11], [@CR12]). In yeast, pseudo-double HJs are thought to form at stalled forks by strand invasion and D-loop formation (template switch) as an error-free DNA-damage bypass mechanism compared to TLS polymerases, which often replicate across lesions in an error-prone manner (Branzei and Foiani [@CR9]). Since BRCA2^Δex27^ cannot carry out RAD51-mediated strand invasion (Thorslund and West [@CR60]), 'hemicatenation' (HR) in mammals may result instead from BRCA2/RAD51-mediated strand switching: twisting/melting dsDNA into ssDNA and, thus, displacement of both lagging and leading strands and their subsequent annealing into one harmless DSB end, flipping out the chicken foot, recruiting/activating ATR, ATM and DNA-PK to terminate HR within an intact chromosome (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5A model for the BRCA2/RAD51 pathway in the response to stalled forks. After their recruitment by BRCA1/MRN, BRCA2/RAD51 complexes may act in concert to (i) disassemble chromatin (*A*); (ii) maintain SCC/alignment (*B*); (iii) effectuate strand-switching and thereby recruit/activate ATR to enhance SCC/alignment (*C*); (iv) provide one DSB end, and thereby activate ATM and DNA-PK (*D*); and (v) twist the DSB end after its processing at least by error-free TLS polymerases into leading and lagging strands that would anneal back with the original templates, and thereby yield a hemicatenane (*E*). If needed, the harmless DSB end (*D* and *F*) may engage in HR, NHEJ or SSA between neighbouring stalled forks during termination of the replication (S) phase (not shown). By interfering with ATR recruitment/activation, short EMSY could induce RFR (RAD51-independent HR) and chicken-foot formation (*F*). HJ-resolving enzymes against crossover, such as BLM and WRN, may prevent fork collapse (*G*) by competing with HJ-nicking enzymes (*red arrows*) at the expense of CIN. Unlike hyper-recombination, BRCA2/RAD51-mediated strand switching at either stalled forks (hemicatenation/RFR) or DSBs does not require RAD51-filament formation, in which case the fourfold decrease in HR repair of I-*Sce*I-induced DSBs by short EMSY could be attributed to apoptosis/senescence rather than decreased efficiency of strand switching. Consistently, meiotic HR does not require the loading of RAD51 oligomers by BRCA2 at programmed DSBs, since BRCA2^∆ex27^ KO mice are as fertile as wild-type animals, except that they exhibit hypersensitivity to IR, senescence and reduced life span. Thus, whereas BRCA2/RAD51-mediated strand switching ensures survival, maintains chromosomal stability and acts as an anti-cancer barrier, SCRS and RAD51-mediated strand exchange/invasion can compete with RFR for ssDNA and thereby decrease the likelihood of forks collapse at the expense of CIN and human diseases. Only abnormally proliferating cells crippled in an essential gene are prone to gene mutation/reversion and fork collapse

In support of this, (a) its mini-homologs Brh2 and CeBRC2 that each contains only one RAD51-binding BRC motif and one ssDNA-binding domain possess the ability to twist dsDNA into both D-loops and ssDNA and carry out SSA (Petalcorin et al. [@CR50]; Mazloum et al. [@CR45]; Fig. [4](#Fig4){ref-type="fig"}b). BRCA2^Δex27^ would be expected to conduct such reactions with higher efficiency, as it still possesses eight dsDNA- and ssDNA-binding motifs through its interaction with RAD51, given that RAD51 binds to ssDNA (5′ or 3′) and dsDNA with comparable affinities (Forget and Kowalczykowski [@CR24]). In addition, the binding of RAD51 oligomers to the homologous dsDNA partner inhibits DNA strand-exchange/invasion in vitro and can be modulated by BRC repeats (Forget and Kowalczykowski [@CR24]). In this case, BRCA2/RAD51 complexes together with free RAD51 oligomers may also stabilize replication forks by holding SCs aligned, acting as bridges until activation of replication/checkpoint that would disrupt RAD51 oligomers into monomers and recruit bona fide cohesins (Fig. [5](#Fig5){ref-type="fig"}). (b) Mouse embryonic stem (ES) cells expressing BRCA2^Δex27^ exhibit heightened efficiency of SSA at I-*Sce*I-induced DSBs and hyper-sensitivity to IR, but maintain both G1/S and G2/M checkpoints and resistance to UV radiation as wt ES cells (Morimatsu et al. [@CR47]; Jasin [@CR36]; Gudmundsdottir and Ashworth [@CR29]), indicating that BRCA2^Δex27^ is still efficient in recruiting/activating at least ATR and DNA-damage repair by error-free TLS, NER, BER/SSBR, or mismatch repair (MMR) (Branzei and Foiani [@CR10]). MMR key proteins are also components of BASC (Wang et al. [@CR68]), and although dispensable for survival (Friedberg and Meira [@CR25]), they have also been implicated in DDR and the processing of HR intermediates containing HJs or branched DNA in collaboration with NER proteins (Villemure et al. [@CR62]). (c) NER, transcription-coupled NER and PCNA-dependent pathways of BER/SSBR also require BRCA1, BRCA2, RPA, RAD51 and ATR (Le Page et al. [@CR40]; Bogliolo et al. [@CR7]; Daboussi et al. [@CR19]; Aboussekhra and Al-Sharif [@CR2]; Auclair et al. [@CR5]). (d) As the localization of activated ATM and BRCA2/RAD51 complexes by BRCA1/MRN is needed for ATR activation in response to DSBs, that of ATR also seems to be required for ATM and DNA-PK activation in response to stalled forks (Stiff et al. [@CR59]; Yajima et al. [@CR74]). (e) BRCA1 and ATR have been shown to enforce TOPII-mediated decatenation G2 checkpoint (Deming et al. [@CR20]). In normal proliferating cells, all replication forks would stall at termination of the S phase by catenanes, positive DNA supercoils that develop under torsional stress between advancing/colliding forks, acting as topological barriers, activating TOPII-mediated decatenation of SCs to allow completion of the S phase, chromosome condensation and segregation during the G2 and M phases (Deming et al. [@CR20]; Branzei and Foiani [@CR10]). Thus, with its HAT on doing the twist and changing partners at DNA, BRCA2^Δex27^ still has the ability to provide a finger to any stalled fork, and thereby act upstream and downstream of PIKKs, orchestrating at least S/G2/M-transition checkpoints and mutation-avoidance systems as full-length BRCA2, ensuring the accuracy rather than efficiency of such DNA transactions that can be carried out in vitro and by organisms that do not possess BRCA homologs.

In addition, unlike humans, *BRCA2*^Δex27^ KO mice or mice heterozygous for BRCA2-truncating mutations are not spontaneously more cancer-prone than wt animals (Donoho et al. [@CR21]; Evers and Jonkers [@CR23]). Moreover, unlike BRCA2-deficient human cells (Abaji et al. [@CR1]), mouse cells expressing BRCA2^Δex27^ have not been reported to undergo hyper-recombination or SCRS (Gudmundsdottir and Ashworth [@CR29]; Moynahan and Jasin [@CR48]). These two 'mutator' phenotypes and cancer predisposition highlight the importance of both replication/checkpoint in chromosomal stability and the difference between human and mouse BRCA2. Whereas human BRCA2 contains one nuclear localization signal (NLS) at the C-terminal domain, mouse BRCA2 possesses an additional NLS at the N-terminal domain (Jasin [@CR36]). The majority of inherited, cancer-eliciting BRCA2 mutations encode truncated proteins as in CAPAN-1 cells, where BRCA2 is truncated at exon 11, weakly expressed, and exclusively localized in the cytoplasm, allowing both hyper-recombination and SCRS to take place (Abaji et al. [@CR1]). Conversely, truncated mouse BRCA2^Δex27^ is expressed normally and localizes exclusively in the nucleus (Jasin [@CR36]).

Hyper-recombination and its hallmarks are characteristic features of not only *BRCA*-deficient and *BRCA*-haploinsufficient tumor cells, but also normal breast epithelial cells and lymphocytes from healthy carriers of *BRCA* mutations, indicating that a 'single hit' in a chromosomal stability gene is sufficient to deregulate HR and induce CIN and the emergence of pre-cancerous lesions (Cousineau and Belmaaza [@CR18]). Although somatic *BRCA* mutations are scarce in sporadic breast cancer, representing less than 1%, the remaining cases are either *BRCA1*- or *BRCA2*-haploinsufficient due to loss (deletion/aneuploidy) or epigenetic silencing of wt *BRCA* alleles (Welcsh and King [@CR70]), and all exhibit amplification of oncogenes most notably *EMSY*, *MYC*, *E2F-1*, *CyclinD1*, or *AKT*, or loss of tumor-suppressor genes, such as *PTEN*, *p53*, or *RB* (Kenemans et al. [@CR39]). Similar to *EMSY*, amplification/overexpression of other oncogenes, such as *MYC* or *E2F-1*, has also been shown to induce fork stalling and CIN as well as fork collapse into DSBs, activating ATM and not ATR, triggering apoptosis/senescence, acting as an anti-cancer barrier (Hong et al. [@CR33]; Halazonetis et al. [@CR30]). Thus, oncogenes can behave as tumor suppressors. Similarly, aneuploidy also acts both oncogenically and as a tumor suppressor (Weaver et al. [@CR69]).

Hyper-recombination and its hallmarks are also characteristic features of *PARP1*- and *ATM*-deficient cells or KO mice (Claybon et al. [@CR15]) and cells disrupted in DNA-PK (Allen et al. [@CR4]) or MMR proteins (Villemure et al. [@CR62]), or cells expressing p53 mutant proteins (Daboussi et al. [@CR19]; Akyuz et al. [@CR3]; Lemelin et al. [@CR41]) or derived from patients with CIN syndromes, such as ataxia telangiectasia, Bloom's syndrome, Werner's syndrome, and Fanconi's anemia, associated with mutations in *ATM*, *BLM*, *WRN*, and several *FANC* genes, respectively (Meyn [@CR46]). Consistently, the most notable of *FANC* genes include *FANC*-D1 (*BRCA2*), *FANC*-D2, *FANC*-J (*BRIP1*, *BACH1*), and *FANC*-N (*PALB2*) (Walsh and King [@CR66]). In addition, similar to *BRCA1* and *BRCA2*, the inheritance of a mutated copy of *ATM*, *PALB2*, *BRIP1*, *p53* or *CHK2* (mutated in Li-Fraumeni syndrome), *MRE11* (mutated in ataxia telangiectasia-like disease), *NBS1* (mutated in Nijmegen breakage syndrome), or *PTEN* (mutated in Cowden disease) also confers a high lifetime risk of developing breast cancer (Walsh and King [@CR66]). Cancer predisposition aside, patients with these syndromes also suffer from several other illnesses, such as neurological and cardiovascular diseases, diabetes, immunodeficiency, anemia, infertility, or premature aging as patients with Xeroderma pigmentosum, Cockyane syndrome, Trichothiodystrophy and Rothmund-Thompson syndrome, associated with mutations in components of NER, transcription-coupled NER, and RecQ-like DNA helicases such as BLM and WRN (Shiloh [@CR55]; Vogelstein and Kinzler [@CR65]; Branzei and Foiani [@CR10]).

In conclusion, we briefly wielded the 'triple-edged' sword of HR: life, death and human diseases. That BRCA1 and BRCA2 act upstream of PIKKs as the masters of chromosomal stability may also explain: (a) why among all the inherited, breast cancer-eliciting gene mutations identified to date, *BRCA1* and *BRCA2* represent the majority of cases, whereas *ATM*, *CHK2*, p*53*, *MRE11*, *RAD50*, *PALB2*, *BRIP1* (*BACH1*) and *PTEN* each accounts for approximately 1% of the remaining cases (Walsh and King [@CR66]); (b) why in sporadic breast cancer, the majority if not all cases are either *BRCA1*- or *BRCA2*-haploinsufficient (Welcsh and King [@CR70]); and (c) why breast cancer exhibits decreased or increased levels of almost exclusively those proteins that interact with BRCA1 and BRCA2. This indicates that (a) cancer may be a gene-dosage disease, in which tumor-suppressor genes and oncogenes are two facets of the same process with dosage amount acting both as a cancer promoter and an anti-cancer barrier through fork stalling and collapse, respectively; and (b) tissue specificity of the tumor-suppressive or -promoting property of all these housekeeping chromosomal stability genes may be determined by tissue-specific DNA-damaging agents, such as estrogens, anti-estrogens and phytoestrogens in breast cancer. The anti-cancer facet of such compounds could be enhanced if employed as tissue-specific carriers of potent DSB-inducing drugs.
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